Do older patients benefit from HMAs + venetoclax in acute leukemias of ambiguous lineage?

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub had the opportunity to speak to Justin Kaner, Weill Cornell Medicine, New York, US. We asked, Do older patients benefit from hypomethylating agents (HMAs) + venetoclax in acute leukemias of ambiguous lineage (ALAL)? 

Kaner discusses the treatment of patients with ALAL, including patients with mixed phenotype acute leukemia and acute undifferentiated leukemia. He then highlights results from a retrospective analysis comparing outcomes of patients with ALAL treated with HMAs plus venetoclax with patients who received intensive chemotherapy. Kaner concludes by raising the need for further investigation into HMAs plus venetoclax as a treatment option for patients with ALAL, particularly in those who are older and ineligible for intensive treatment.